Complement cash

True North Therapeutics Inc.’s first clinical data for lead molecule TNT009 convinced new investor HBM Healthcare Investments to co-lead this month’s $45 million series D round.

The other co-leads were new investor Redmile Group and existing investor Perceptive Advisors. They were joined by new investor Franklin Templeton Investments and undisclosed existing investors. ...